ClinicalTrials.gg
Active, not recruitingNCT06425549BE TOGETHERUpdated Sep 18, 2026

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of bimekizumab and ustekinumab in Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL. Active, not recruiting at 42 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
9th of 20
176 · median 161
Started
2024
with 1 other
Phase 3
10 of 20
2 open now
Registered
16th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 10 in phase 3, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

Keywords

  • bimekizumab
  • BKZ
  • ustekinumab
  • paediatric study participants
  • children
  • adolescents
  • Psoriasis
  • PSO
  • Plaque Psoriasis
  • Paediatric Psoriasis
  • Pediatric Psoriasis
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the /assent according to local regulation
  • Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit
  • Study participant meets the following at both the Screening and Baseline Visits:

    1. Body surface area (BSA) affected by PSO ≥10%
    2. . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
    3. . Psoriasis Area and Severity Index (PASI) score ≥12 OR

PASI score ≥10 plus at least 1 of the following:

i) facial involvement ii) Clinically relevant genital involvement iii) Clinically relevant hand and foot involvement

  • Study participant is a candidate for systemic PSO therapy and/or photo/chemotherapy and for treatment with ustekinumab per labeling
  • Study participant has body weight ≥15 kg and for age percentile of ≥5 at Screening

Exclusion criteria

Exclusion Criteria:

  • Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17
  • Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
  • Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
  • History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
  • Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
  • Study participant has previously received bimekizumab
  • Study participant has previously received ustekinumab
  • Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
  • Study participant has the presence of active suicidal ideation, or positive suicide behavior
  • Study participant diagnosed with severe depression in the past 6 months (prior to Screening) should be excluded
  • Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    bimekizumab

    Study participants randomized to this arm receive bimekizumab dosage regimen 1 at pre-specified timepoints during the Initial Treatment Period (16 weeks). They continue to receive bimekizumab dosage regimen 2 in the Maintenance Period (32 weeks). Under certain conditions study participants may be offered to continue on bimekizumab dosage regimen 2 in the Open-label Extension (OLE) Period (104 weeks).

    Drug: bimekizumab · Drug: placebo

  • Active comparator
    ustekinumab

    Study participants randomized to this arm receive ustekinumab at pre-specified timepoints during the Initial Treatment Period (16 weeks) and during the Maintenance Period. Under certain conditions participants may switch to bimekizumab dosage regimen 1 (16 weeks) and continue with bimekizumab dosage regimen 2 in the last 16 weeks of the Maintenance Period. Under certain conditions study participants may be offered to participate in the OLE Period also receiving bimekizumab dosage regimen 2.

    Drug: bimekizumab · Drug: ustekinumab · Drug: placebo

Interventions

  • Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.

    Also known as: BKZ, UCB4940

  • Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.

    Also known as: USTE

  • Drugplacebo

    Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.

06

What researchers measure

Primary outcomes

  1. Psoriasis Area Severity Index 90 (PASI90) response at Week 16

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  2. Investigator´s Global Assessment (IGA) 0/1 response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline.

    Time frame: Week 16

Secondary outcomes

  1. PASI75 response at Week 4

    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 4

  2. PASI100 response at Week 16

    A PASI100 responder is defined as a subject that achieves 100% reduction from Baseline in the PASI score. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  3. PASI90 response at Week 48

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 48

  4. IGA 0/1 response at Week 48

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline.

    Time frame: Week 48

  5. PASI100 response at Week 48

    A PASI100 responder is defined as a subject that achieves 100% reduction from Baseline in the PASI score. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 48

  6. IGA 0 response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA 0 response (Clear) is defined as clear \[0\] with at least a two-category improvement from Baseline.

    Time frame: Week 16

  7. IGA 0 response at Week 48

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA 0 response (Clear) is defined as clear \[0\] with at least a two-category improvement from Baseline.

    Time frame: Week 48

  8. Incidence of treatment-emergent adverse events (TEAE)s

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.

    Time frame: From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

  9. Incidence of serious TEAEs

    An serious adverse event (SAE) must meet 1 or more of the following criteria: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.

    Time frame: From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

  10. Incidence of TEAEs leading to discontinuation of Investigational Medicinal Product (IMP)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason.

    Time frame: From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

  11. Incidence of TEAEs leading to withdrawal from the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks. This measure considers any TEAE leading to permanent withdrawal from study.

    Time frame: From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

  12. Incidence of TEAEs predefined as safety topics of interest

    Safety topics of interest are infections (serious, opportunistic, fungal, and tuberculosis), inflammatory bowel disease, and injection site reactions.

    Time frame: From Baseline (Week 0) to Week 48 and to End of Safety Follow-up (up to Week 164)

  13. Change from Baseline in vital signs (systolic blood pressure)

    Blood pressure will be measured in millimeters of mercury (mmHg).

    Time frame: From Baseline (Week 0) up to Week 48

  14. Change from Baseline in vital signs (diastolic blood pressure)

    Blood pressure will be measured in millimeters of mercury (mmHg).

    Time frame: From Baseline (Week 0) up to Week 48

  15. Change from Baseline in vital signs (pulse rate)

    Pulse rate will be measured in beats per minute (beats/min).

    Time frame: From Baseline (Week 0) up to Week 48

  16. Incidence of clinically significant physical examination findings reported as TEAEs

    Clinically significant findings or worsening of previous findings since the physical examination at Baseline will be reported as TEAEs.

    Time frame: From Baseline (Week 0) up to Week 48

  17. Change from Baseline in height (growth assessment)

    Growth assessment, as assessed by the change from Baseline in height.

    Time frame: From Baseline (Week 0) up to Week 48

  18. Change from Baseline in weight (growth assessment)

    Growth assessment, as assessed by the change from Baseline in weight.

    Time frame: From Baseline (Week 0) up to Week 48.

  19. Change from Baseline in hematology parameters (platelet count)

    Platelets will be measured in number of platelets per liter (10\^9/L).

    Time frame: From Baseline (Week 0) up to Week 48

  20. Change from Baseline in hematology parameters (erythrocytes)

    Erythrocytes will be measured in number of red blood cells per liter (10\^12/L).

    Time frame: From Baseline (Week 0) up to Week 48

  21. Change from Baseline in hematology parameters (hemoglobin)

    Hemoglobin will be measured in grams per liter (g/L).

    Time frame: From Baseline (Week 0) up to Week 48

  22. Change from Baseline in hematology parameters (hematocrit)

    Hematocrit will be measured in volume percentage (%) of red blood cells in blood.

    Time frame: From Baseline (Week 0) up to Week 48

  23. Change from Baseline in biochemistry parameters (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase)

    Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase will be measured in units per liter (U/L).

    Time frame: From Baseline (Week 0) up to Week 48

  24. Change from Baseline in hematology parameters (basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes)

    Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes will be measured in number of white blood cells per liter (10\^9/L).

    Time frame: From Baseline (Week 0) up to Week 48

  25. Change from Baseline in biochemistry parameters (glucose, potassium, sodium, calcium)

    Glucose, potassium, sodium and calcium will be measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 0) up to Week 48

  26. Change from Baseline in biochemistry parameters (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine)

    Clinical chemistry parameters will be measured in micromols per liter (μmol/L).

    Time frame: From Baseline (Week 0) up to Week 48

  27. Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) total score at Week 16

    The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week. The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).

    Time frame: Week 16, compared to Baseline

  28. Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) total score at Week 48

    The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week. The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).

    Time frame: Week 48, compared to Baseline

  29. Change from Baseline in Childhood Health Assessment Questionnaire (CHAQ) disability index at Week 16 for study participants with juvenile PsA prior to Baseline

    The CHAQ is a questionnaire designed to capture physical function in children and adolescents with juvenile rheumatoid arthritis. The CHAQ comprises 2 indices, Disability and Discomfort. The Disability Index assesses the degree of difficulty experienced over the past week across 30 items in the following 8 categories of the daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. The Disability Index ranges from 0 (no disability) to 3 (maximum disability). Discomfort is determined by the presence of pain, as measured by a 100-mm visual analogue scale (VAS). In addition, a final global assessment item asks study participants to rate how they are doing by placing a mark on a 100 mm VAS.

    Time frame: Week 16, compared to Baseline

  30. Change from Baseline in Peak Pruritus numerical rating scale (NRS) score at Week 16

    The Peak Pruritus NRS measures the worst level of itching in the past 24 hours on an 11-point scale ranging from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Week 16, compared to Baseline

  31. Plasma bimekizumab concentrations prior to and following IMP administration over the Initial Treatment Period, over the Maintenance Period, and over the OLE Period

    Plasma bimekizumab concentrations prior to investigational medicinal product (IMP) administration and following investigational medicinal product (IMP) administration

    Time frame: From Baseline to End of OLE Period (up to 144 weeks)

  32. Plasma anti-bimekizumab antibodies prior to and following IMP administration over the Initial Treatment Period, over the Maintenance Period, and over the OLE Period

    Anti-bimekizumab antibody (AbAb) detection prior to investigational medicinal product (IMP) administration and following investigational medicinal product (IMP) administration

    Time frame: From Baseline to End of OLE Period (up to 144 weeks)

07

Study locations

42 sites
  • Ps0021 50162
    Fountain Valley, California 92708, United States
  • Ps0021 50161
    Los Angeles, California 90045, United States
  • Ps0021 50196
    Northridge, California 91325, United States
  • Ps0021 50344
    Indianapolis, Indiana 46250, United States
  • Ps0021 50084
    Charleston, South Carolina 29425, United States
  • Ps0021 50201
    Arlington, Texas 76011, United States
  • Ps0021 50355
    Dallas, Texas 75235, United States
  • Ps0021 40121
    Brussels, Belgium
  • Ps0021 50618
    Mississauga, Canada
  • Ps0021 50357
    St. John's, Canada
  • Ps0021 40748
    Plzen-bory, Czechia
  • Ps0021 40740
    Bad Bentheim, Germany
  • Ps0021 40515
    Berlin, Germany
  • Ps0021 40138
    Bonn, Germany
  • Ps0021 40356
    Dresden, Germany
  • Ps0021 40023
    Erlangen, Germany
  • Ps0021 40645
    Frankfurt am Main, Germany
  • Ps0021 40758
    Hamburg, Germany
  • Ps0021 40249
    Kiel, Germany
  • Ps0021 40747
    Mainz, Germany
  • Ps0021 40177
    Münster, Germany
  • Ps0021 40746
    Debrecen, Hungary
  • Ps0021 40744
    Kaposvár, Hungary
  • Ps0021 40745
    Szeged, Hungary
  • Ps0021 40440
    Ancona, Località Torrette, Italy
  • Ps0021 40749
    Catania, Italy
  • Ps0021 40085
    Pisa, Italy
  • Ps0021 40567
    Roma, Italy
  • Ps0021 20071
    Nagasaki, Japan
  • Ps0021 20033
    Nagoya, Japan
  • Ps0021 20337
    Shimotsuga-gun, Japan
  • Ps0021 40741
    Bialystok, Poland
  • Ps0021 40625
    Lodz, Poland
  • Ps0021 40832
    Lodz, Poland
  • Ps0021 40091
    Nowa Sól, Poland
  • Ps0021 40737
    Rzeszów, Poland
  • Ps0021 40743
    Szczecin, Poland
  • Ps0021 40334
    Wroclaw, Poland
  • Ps0021 40738
    Wroclaw, Poland
  • Ps0021 40750
    Alicante, Spain
  • Ps0021 40751
    Esplugues de Llobregat, Spain
  • Ps0021 40752
    Granada, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2028, 49 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 49 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 22, 2024
StartActual
Jun 25, 2024
Primary completionEst.
Aug 21, 2028
CompletionEst.
Nov 8, 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06425549
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Jun 25, 2024
Primary completion
Aug 21, 2028 (estimated)
Completion
Nov 8, 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion